Sputnik v meets the primary endpoint of safety in the phase 2 clinical trial in india

Hyderabad, india--(business wire)--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy) announced today that the independent data and safety monitoring board (dsmb) has reviewed the safety data from the phase 2 clinical trial of the sputnik v vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications. the phase 2 study of sputnik v was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-control
RDY Ratings Summary
RDY Quant Ranking